Hinge Health Earnings Call Signals Profitable Growth

Hinge Health, Inc. Class A ((HNGE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Hinge Health, Inc. Class A delivered an upbeat earnings call that underscored strong momentum across its business. Management highlighted a sizable revenue beat, widening margins, robust free cash flow, and a guidance raise, all while acknowledging risks around device costs, seasonality, and a measured rollout of new programs such as migraine care.

Revenue Beat and Strong Top-Line Growth

The company posted Q1 revenue of $182 million, a 47% jump from $124 million a year ago and comfortably ahead of its $171–$173 million guidance range. Management framed this outperformance as evidence that demand for its digital musculoskeletal solutions remains resilient despite broader benefits-budget scrutiny.

Calculated Billings Expansion

Last twelve months calculated billings climbed to $770 million, up 52% from $507 million in the prior-year period, signaling strong underlying contract activity. Executives stressed that this growth reflects both new client wins and deeper penetration within existing accounts, pointing to durable demand rather than one-off deals.

Robust Margin and Profitability Improvement

Gross margin rose to 85%, a 400-basis-point improvement year over year, while operating margin expanded to 25% from 12% in Q1 2025. Operating income reached $46 million, topping guidance of $30–$32 million, as the company benefited from scale efficiencies and a slower-than-planned pace of hiring.

Free Cash Flow and Balance Sheet Strength

Free cash flow surged to $42 million, roughly 10 times the prior-year level, translating to a 23% free cash flow margin versus 3% a year earlier. With $407 million in cash and equivalents at quarter end, management emphasized that the balance sheet provides ample flexibility for continued investment while still returning capital to shareholders.

Raised Full-Year Guidance

Hinge Health raised its full-year 2026 revenue outlook to $798–$804 million, implying about 36% growth at the $801 million midpoint. The company also lifted its income from operations guidance to $205–$215 million, targeting a 26% operating margin at the midpoint and signaling confidence that recent momentum can be sustained.

Product Expansion: Migraine Program and FDA Clearance

The company launched a migraine care program anchored by Enso, which secured 510(k) clearance from regulators for migraine treatment. Early trial data showed 56% of participants experienced pain reductions from severe or moderate to mild or none with at least one waveform, and participants were 1.9 times more likely to reduce pain versus placebo.

Early Commercial Uptake of Migraine Program

Commercial traction for the migraine program has been rapid, with more than 125 clients signing on within weeks of launch. Management noted that these clients collectively cover over 2 million eligible lives, underscoring buyer interest even though material revenue benefits are not expected until later years.

Commercial Momentum and Network Growth

The sales pipeline is substantially larger than a year ago, with small and mid-sized business opportunities more than doubling. Hinge Select expanded to 4,100 provider locations and secured broader distribution through a national pharmacy benefit manager and three of the five largest national health plans.

Shift Toward Engagement-Based Pricing

Roughly 80% of contracted lives now sit on engagement-based pricing, which aligns revenue with user adoption and outcomes. However, management noted that around 20% of lives remain on legacy subscription structures, and the gradual migration may temper near-term average revenue per user upside.

Capital Deployment and Share Count Reduction

The company executed a $105 million share repurchase in the quarter, retiring 2.5 million shares. Diluted weighted average shares fell to 82.4 million, supporting diluted net income per share of $0.45 and signaling a willingness to return excess capital while growth investments continue.

Limited Near-Term Revenue from Migraine

Despite strong early adoption, management cautioned that the migraine program will contribute minimal revenue in 2026. They expect more meaningful financial impact beginning in 2027, framing the initiative as a longer-term growth driver rather than a near-term earnings lever.

Seasonal Sales Cycle Concentration

Executives reminded investors that most new client closings historically occur in the back half of the year. This seasonality concentrates revenue realization and introduces timing risk, making second-half execution critical to meeting or beating full-year targets.

Decision to Sit Out CMS ACCESS Program

Hinge Health chose not to participate in a federal ACCESS program due to concerns over clinical oversight and program design. While this decision avoids operational complexity, it may also delay or limit exposure to certain government populations, representing a trade-off in the company’s expansion strategy.

Device Deployment Cost Pressure

Enso device deployments roughly doubled in 2025 versus 2024, and management plans another 40% increase in 2026 as the migraine program ramps. These volumes can pressure cost of goods and gross margins, though leadership expects care-team productivity gains and scale efficiencies to offset part of the impact.

Temporary Hiring Slowdown and Future Costs

A deliberate slowdown in hiring helped drive the recent margin gains, particularly in operating income. Management signaled that they plan to “catch up” on hiring later in the year, which could lift operating expenses and moderate some of the current margin expansion as they invest ahead of growth.

Forward-Looking Guidance and Outlook

For Q2, the company guided to revenue between $104 million and $196 million and income from operations of $47–$49 million, targeting a 25% margin at the midpoint. Management indicated that roughly half of the full-year guidance increase stems from higher yield and half from lives growth, with device deployment, engagement-based pricing, and network expansion all expected to support sustained double-digit growth.

Hinge Health’s latest earnings call painted the picture of a company balancing aggressive growth with disciplined profitability. Investors will be watching whether management can navigate device cost pressures, hiring ramp-up, and seasonal sales patterns while continuing to convert a robust pipeline into durable revenue and cash flow gains.